Great Bay Bio 大湾生物

Happy New Year from Great Bay Bio 大湾生物🎉 As we step into 2025, the team at Great Bay Bio 大湾生物 reflects on a year of growth and innovation. We would like to extend our warmest wishes to our partners, colleagues, and friends around the world. 🌟 May the new year bring you joy, success, and exciting new opportunities. 🎁 #HappyNewYear2025 #NewYearNewBeginnings #GBB #GreatBayBio

Great Bay Bio 大湾生物 was honored as one of the Top 50 Innovative Biotechnology Companies in Guangdong-Hong Kong-Macao Greater Bay Area Award 2024. We are also proud to have received the “Most Valuable Investment Enterprise 2024” and “The Pioneer Enterprise”.   This recognition highlights our unwavering commitment to advancing drug development by leveraging cutting-edge technologies like AI, big data mining, and automation. Our AI-enabled platforms empower the full spectrum of drug discovery and CMC development, delivering faster and more efficient solutions to our domestic and international partners.   #GreatBayBio #GBB #Innovation #Biotech #DrugDevelopment #Investment #BiotechLeadership #GreaterBayArea

🎄 Merry Christmas from Great Bay Bio 大湾生物! 🎄   As we reflect on a year full of innovation and growth, the team at Great Bay Bio would like to extend our warmest holiday wishes to our partners, colleagues, and friends worldwide. 🌟   May this festive season bring joy, peace, and new opportunities. 🎁   #MerryChristmas #GBB #GreatBayBio 

December 16, 2024 Great Bay Bio 大湾生物 is thrilled to announce the successful first close of its Series B financing round. This milestone was achieved with the round led by a syndication of a well-known strategic investment institution and its affiliate, Tiger Jade Pebble Accelerator. The financing also attracted participation from new investors, including a Hong Kong-based family office, the Hong Kong Science and Technology Parks Venture Fund, as well as continued support from an existing global life science strategic investor. The funds will be instrumental in advancing GBB’s AI-enabled drug development ecosystem and accelerating the global adoption of its innovative solutions. This marks a significant step forward in transforming biologics development on an international scale. GBB’s commercialization efforts have been gaining momentum, fueled by technical breakthroughs and market-driven solutions. In the cell line development business, GBB’s site-specific cell line development platform, AlfaCell, has enabled customers to secure clinical trial approvals from both China’s National Medical Products Administration (#NMPA) and the U.S. Food and Drug Administration (#FDA). These cell lines have also been successfully applied in multiple projects, with partners expressing satisfaction with improved yields and shorter development timelines, especially for multi-specific antibodies. Additionally, GBB has enhanced its cell culture capabilities by establishing its own ISO 9001:2015-certified cell culture powder manufacturing line, further ensuring a high-quality and secure supply chain for partners. These achievements have positioned GBB as a trusted partner for leading MNCs in the life sciences, specialty chemicals, and pharmaceutical CDMO sectors, meeting the global demand for faster and more efficient new product development. For details, please refer to https://lnkd.in/gFPEifUX. #GreatBayBio #GBB #financing #seriesB #HKSTP #fundraising #biotechnology #ai #technology #bioprocessing #innovation #artificialintelligence #cellline #CMC #bioproduction #investment

🗣 Join us at Antibody Engineering & Therapeutics 2024 in San Diego! 📅 Date: December 15–18, 2024 📍 Location: Marriott Marquis San Diego 📌 Booth: #219 Great Bay Bio 大湾生物 business and technical teams will be at #AET2024, showcasing our innovative approach to biologics development. By integrating AI, big data mining, and automation, we have established an intelligent ecosystem (Alfa-ecosystem 1.0) to develop biological molecules from targets to mAb/BsAb at early stages of #CMC within 8 months. Please drop by our booth #219 and learn more. See you at AET 2024! #GBB #GreatBayBio #Biologics #AntibodyEngineering

 🗣️ Join us at Antibody Engineering & Therapeutics 2024 in San Diego!   Great Bay Bio 大湾生物 business and technical teams will attend #AET from December 15 to 18. GBB is committed to integrating AI, big data mining, and automation into drug development, driving a disruptive revolution of biologics development. We have established an intelligent ecosystem (Alfa-ecosystem 1.0) to develop biological molecules from targets to mAb/BsAb at early stages of CMC within 8 months.   Feel free to drop by our booth #219 and learn more. See you at AET 2024!   #GreatBayBio #GBB #AET2024 #Bioprocessing #AntibodyEngineering #Therapeutics #Biotechnology #Biotech

博采创新思想，览阅先锋企业，会见时代人物！ 第十五届中国（泰州）国际医药博览会（简称：#医博会）将于11月29-30日，在中国医药城会展交易中心（江苏省泰州市）举行。Great Bay Bio 大湾生物首席技术官齐凯博士将发表主题演讲，与众多技术专家、学者、投资者等，共同探讨前沿生物科技在创新药与消费医疗等领域的创新成果转化，实现生物技术价值创造与医健产业投资价值的双向奔赴。 本次医博会特设20场专题交流活动促进跨界融合与产业生态构建，大湾生物齐凯博士应邀出席，并将于11月30日下午14:20-14:40在E1馆-会议区1，以“AI生态系统在大分子药物创新中的应用”为主题进行演讲，深度阐述大湾生物AI生态系统如何高效赋能大分子药物创新开发，助力客户产品开发更快更好。大湾生物展位号E21、E22，期待您莅临现场交流。 #GreatBayBio #GBB #医博会 #生物制药

#Merck Digitech Summit 2024 The Merck Digitech Summit 2024 was successfully held in Shanghai recently. The summit focused on "Empowering Data & Digital, Innovating Technology", exploring innovative concepts for sustainable business growth. Great Bay Bio was honored to participate in the event, where we showcased our Intelligent Drug Development Ecosystem, which integrates cutting-edge #AI, #automation, and big #data analytics to transform biopharmaceutical development. Dr. Kane Qi, our CCO, shared insights on how this ecosystem revolutionizes drug discovery and biomanufacturing, empowering faster and more efficient product development. By applying AI across every stage of the biopharma process—from molecular sequence generation and optimization to cell line development and culture media optimization—GBB is enabling faster, more efficient, and higher-quality drug development. This end-to-end platform empowers clients to accelerate product development, bringing biological drugs to market more quickly. #GBB #GreatBayBio #AI #Biotech #DrugDevelopment #Innovation #Biopharma

🌟 “Some patients suffering from life-threatening diseases are going broke to buy drugs. Companies need to make a profit to drive innovation. This is a complex reality. I stand in the middle and see both perspectives.” – Kingsley Leung, CFA, Co-founder & Chairman of Great Bay Bio 大湾生物.   On November 19, 2024, Kingsley Leung, CFA shared his inspiring journey and mission with #Tatler Asia, highlighting how Great Bay Bio is leveraging AI to reshape the #pharmaceutical industry. We aim to create win-win solutions that benefit pharmaceutical companies and patients by accelerating drug development and reducing costs.   Founded in 2019, GBB focuses on addressing the industry’s most pressing challenges, such as long timelines, high costs, and inefficiencies in drug development. Leveraging proprietary AI-driven platforms, GBB accelerates the CMC stage of drug production, tailoring cell culture media to optimize yields and reduce costs. This enables pharmaceutical companies to bring life-saving treatments to market faster and at lower prices—creating a win-win for industry players and patients.   With operations in both Hong Kong and Dongguan, we’re proud to be part of the Greater Bay Area’s dynamic innovation hub, striving to balance cutting-edge science with compassionate care.   👉 Read more here https://lnkd.in/gGk7pd22   #Innovation #Healthcare #AI #DrugDevelopment #SocialImpact #GreatBayBio #GBB #TatlerAsia

The #AlfaMedX platform applies AI technology to the development of cell culture media formulations, establishing a media formulation algorithm platform to develop media suitable for cell growth, protein expression, and cell differentiation, including basal media, fed-batch media, and perfusion media.   💡 Attributes of AlfaMedX 🔹 Defined chemical composition of the culture media and free from any animal-derived components. 🔹Contains amino acids, vitamins, glucose, lipids, inorganic salts, and trace elements; free from growth factors, cholesterol, peptides, hydrolysates, and phenol red. 🔹 The dry powder culture media contains P188 and HT, without L-glutamine.   💡 Advantages of AlfaMedX 🔹 High Titer ·   Protein expression is comparable to or better than commercial culture media. ·   Titer≥75% commercial culture media. 🔹 Optimal Optimization ·   Titer can be optimized to the maximum by utilizing the #AlfaOPA culture media optimization platform. 🔹 Cost-effective ·   Shortens product development cycle ·   Significantly reduces initial investment for customers 🔹 Adaptable ·   Good universality ·   Suitable for cell line culturing of various products   #GreatBayBio #GBB #AlfaMedX #CellCultureMedia #AI #Bioprocessing #Biotechnology  #DrugDevelopment #Innovation #CMC